window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-64619718-7'); Skip to content

Contact us

LinkedIn
Vernalis Research Logo
  • Home
  • About us
    • Our history
    • Our people
    • Careers
  • Our approach
    • Technology
    • Research case studies
  • Partnering
    • Overview
    • Research collaborations
    • Pre-clinical candidates
  • Resources
    • Publications
    • Software
  • News & events
    • Announcements
    • Conferences
Design of LRRK2 crystallographic surrogate
Gallery

Design of LRRK2 crystallographic surrogate

Kinases
Design of LRRK2 crystallographic surrogatevernalis2019-04-26T13:12:43+01:00
Chk1 pre-clinical candidate
Gallery

Chk1 pre-clinical candidate

Kinases
Chk1 pre-clinical candidatevernalis2019-04-30T09:22:53+01:00

We develop and apply fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation.

QUICK LINKS

  • Publications
  • Research case studies
  • Research collaborations
  • Pre-clinical candidates
  • HitGen
  • Glossary
  • COVID-19 Statement


  • Press releases
  • Careers
  • Contact us
  • Sitemap
  • Disclaimer
  • Privacy policy

FIND US

  • Vernalis (R&D) Limited
  • Granta Park
  • Great Abington
  • Cambridge
  • CB21 6GB
  • United Kingdom
© 2019–2021 Vernalis (R&D) Limited. All Rights Reserved. Designed by Douglass Digital
This website uses cookies and third party services. Read our Privacy Policy Ok